logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Modern Dosefinding Designs For Cancer Phase I Trials Drug Combinations And Molecularly Targeted Agents 1st Edition Akihiro Hirakawa

  • SKU: BELL-6990120
Modern Dosefinding Designs For Cancer Phase I Trials Drug Combinations And Molecularly Targeted Agents 1st Edition Akihiro Hirakawa
$ 31.00 $ 45.00 (-31%)

0.0

0 reviews

Modern Dosefinding Designs For Cancer Phase I Trials Drug Combinations And Molecularly Targeted Agents 1st Edition Akihiro Hirakawa instant download after payment.

Publisher: Springer Japan
File Extension: PDF
File size: 1.55 MB
Author: Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui (auth.)
ISBN: 9784431555728, 9784431555735, 4431555722, 4431555730
Language: English
Year: 2018
Edition: 1

Product desciption

Modern Dosefinding Designs For Cancer Phase I Trials Drug Combinations And Molecularly Targeted Agents 1st Edition Akihiro Hirakawa by Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui (auth.) 9784431555728, 9784431555735, 4431555722, 4431555730 instant download after payment.

This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.

Related Products